Protective effect of magnolol-loaded polyketal microparticles on lipopolysaccharide-induced acute lung injury in rats
Related Experiment Video
Updated: Mar 18, 2026
Non-Invasive Endotracheal Administration of Lipopolysaccharide to Induce Acute Lung Injury in Rodents
Published on: December 5, 2025
Tsuimin Tsai1, Chen-Yu Kao2,3, Chun-Liang Chou2
1a Graduate Institute of Biomedical Materials and Tissue Engineering, Taipei Medical University , Taipei , Taiwan ;
Abstract:
Magnolol has shown inhibitory effects on NO production and TNF-alpha production in lipopolysaccharide (LPS)-activated macrophages and LPS-induced acute lung injury; however, the poor solubility of magnolol has hindered its clinical success. In this study, magnolol-loaded microparticles were prepared via single emulsion method from a polyketal polymer, termed PK3. The particle sizes of magnolol-loaded PK3 microparticle is 3.73 ± 0.41 μm, and was suitable for phagocytosis by macrophages and pulmonary drug delivery. PK3 microparticles exhibited excellent biocompatibility both in vitro and in vivo. More importantly, intratracheal delivery of these magnolol-loaded microparticles significantly reduced the lung inflammatory responses at low dosage of magnolol (0.5 mg/kg), and have great clinical potential in treating acute lung injury.
Insights
This study developed magnolol-loaded microparticles using a polyketal polymer (PK3) to overcome magnolol
Area of Science:
- Pharmacology
- Biomaterials Science
- Pulmonary Medicine
Background:
- Magnolol exhibits anti-inflammatory properties, inhibiting nitric oxide (NO) and tumor necrosis factor-alpha (TNF-α) production.
- Poor aqueous solubility of magnolol limits its therapeutic application, particularly in treating lipopolysaccharide (LPS)-induced acute lung injury.
- Developing effective drug delivery systems is crucial for magnolol's clinical translation.
Purpose of the Study:
- To formulate and characterize magnolol-loaded polyketal (PK3) microparticles for enhanced pulmonary drug delivery.
- To evaluate the biocompatibility and efficacy of magnolol-loaded PK3 microparticles in reducing lung inflammation.
- To explore the clinical potential of this formulation for treating acute lung injury.
Main Methods:
- Magnolol-loaded PK3 microparticles were prepared using a single emulsion method.
- Particle size analysis confirmed microparticles suitable for macrophage phagocytosis and pulmonary delivery (3.73 ± 0.41 μm).
- In vitro and in vivo biocompatibility assessments were conducted, alongside evaluation of anti-inflammatory effects following intratracheal administration.
Main Results:
- PK3 microparticles demonstrated excellent biocompatibility in both in vitro and in vivo models.
- Intratracheal delivery of magnolol-loaded PK3 microparticles significantly attenuated lung inflammatory responses.
- Effective reduction in inflammation was observed at a low magnolol dosage (0.5 mg/kg).
Conclusions:
- Magnolol-loaded PK3 microparticles represent a promising formulation for overcoming magnolol's solubility issues.
- This delivery system facilitates efficient pulmonary drug delivery and demonstrates significant anti-inflammatory potential.
- The formulation shows considerable clinical promise for the treatment of acute lung injury.
